Kamada (KMDA) to Release Earnings on Tuesday

Kamada (NASDAQ:KMDAGet Rating) is set to release its earnings data before the market opens on Tuesday, May 17th. Analysts expect Kamada to post earnings of $0.03 per share for the quarter. Kamada has set its FY 2022 guidance at EPS.

Kamada (NASDAQ:KMDAGet Rating) last posted its quarterly earnings results on Tuesday, March 15th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Kamada had a negative return on equity of 0.91% and a negative net margin of 2.15%. The business had revenue of $31.47 million during the quarter, compared to the consensus estimate of $22.24 million. During the same quarter in the previous year, the business posted $0.04 earnings per share. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada stock opened at $4.49 on Thursday. The firm’s 50-day moving average is $5.50 and its 200-day moving average is $5.94. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.16 and a current ratio of 2.41. Kamada has a 1 year low of $4.48 and a 1 year high of $6.96. The company has a market cap of $199.89 million, a P/E ratio of -89.78 and a beta of 0.99.

A number of analysts recently weighed in on KMDA shares. StockNews.com started coverage on shares of Kamada in a report on Thursday, May 5th. They issued a “buy” rating on the stock. Zacks Investment Research cut shares of Kamada from a “buy” rating to a “hold” rating in a report on Friday, May 6th.

Several hedge funds have recently added to or reduced their stakes in KMDA. Morgan Stanley increased its holdings in shares of Kamada by 10.7% in the 2nd quarter. Morgan Stanley now owns 206,619 shares of the biotechnology company’s stock worth $1,203,000 after acquiring an additional 19,953 shares during the period. Millennium Management LLC acquired a new position in Kamada during the 2nd quarter valued at about $73,000. Geode Capital Management LLC increased its stake in Kamada by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 25,878 shares of the biotechnology company’s stock valued at $137,000 after buying an additional 1,856 shares during the period. Dimensional Fund Advisors LP increased its stake in Kamada by 9.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 52,003 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 4,350 shares during the period. Finally, Marshall Wace LLP acquired a new position in Kamada during the 4th quarter valued at about $73,000.

Kamada Company Profile (Get Rating)

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection.

Featured Stories

Earnings History for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.